CR20220053A - Sistema de administración de medicamentos para la administración de agentes antivíricos - Google Patents

Sistema de administración de medicamentos para la administración de agentes antivíricos

Info

Publication number
CR20220053A
CR20220053A CR20220053A CR20220053A CR20220053A CR 20220053 A CR20220053 A CR 20220053A CR 20220053 A CR20220053 A CR 20220053A CR 20220053 A CR20220053 A CR 20220053A CR 20220053 A CR20220053 A CR 20220053A
Authority
CR
Costa Rica
Prior art keywords
delivery
antiviral agents
drug delivery
delivery system
drug
Prior art date
Application number
CR20220053A
Other languages
English (en)
Inventor
Stephanie Elizabeth Barret
Ryan S Teller
Morgan B Giles
Seth P Forster
Athanas Koynoz
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CR20220053A publication Critical patent/CR20220053A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Esta invencion se refiere a novedosos sistemas de administracion de farmacos por implante para la administracion de farmacos antiviricos de accion prolongada. Estas composiciones son utiles para el tratamiento o la prevencion de la infeccion por el virus de la 5 inmunodeficiencia humana (VIH).
CR20220053A 2019-08-13 2020-08-11 Sistema de administración de medicamentos para la administración de agentes antivíricos CR20220053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885968P 2019-08-13 2019-08-13
PCT/US2020/045693 WO2021030306A1 (en) 2019-08-13 2020-08-11 Drug delivery system for the delivery of antiviral agents

Publications (1)

Publication Number Publication Date
CR20220053A true CR20220053A (es) 2022-04-20

Family

ID=74570758

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220053A CR20220053A (es) 2019-08-13 2020-08-11 Sistema de administración de medicamentos para la administración de agentes antivíricos

Country Status (18)

Country Link
US (1) US20220362277A1 (es)
EP (1) EP4013407A4 (es)
JP (1) JP7317210B2 (es)
KR (1) KR20220047307A (es)
CN (1) CN114206336A (es)
AU (1) AU2020328518A1 (es)
BR (1) BR112022002386A2 (es)
CA (1) CA3150272A1 (es)
CL (1) CL2022000318A1 (es)
CO (1) CO2022001356A2 (es)
CR (1) CR20220053A (es)
DO (1) DOP2022000036A (es)
EC (1) ECSP22010042A (es)
IL (1) IL290421A (es)
JO (1) JOP20220033A1 (es)
MX (1) MX2022001765A (es)
PE (1) PE20220707A1 (es)
WO (1) WO2021030306A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638536A2 (en) * 2003-05-30 2006-03-29 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
KR102272235B1 (ko) * 2016-05-12 2021-07-01 머크 샤프 앤드 돔 코포레이션 항바이러스제의 전달을 위한 약물 전달 시스템
WO2018191093A1 (en) * 2017-04-10 2018-10-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
MX2021007544A (es) 2018-12-20 2021-08-11 Merck Sharp & Dohme Llc Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos.

Also Published As

Publication number Publication date
AU2020328518A1 (en) 2022-03-10
EP4013407A1 (en) 2022-06-22
WO2021030306A1 (en) 2021-02-18
CL2022000318A1 (es) 2022-10-07
KR20220047307A (ko) 2022-04-15
MX2022001765A (es) 2022-03-17
BR112022002386A2 (pt) 2022-04-26
US20220362277A1 (en) 2022-11-17
EP4013407A4 (en) 2023-08-23
CA3150272A1 (en) 2021-02-18
JP2022546755A (ja) 2022-11-08
CO2022001356A2 (es) 2022-03-18
IL290421A (en) 2022-04-01
JOP20220033A1 (ar) 2023-01-30
CN114206336A (zh) 2022-03-18
ECSP22010042A (es) 2022-03-31
DOP2022000036A (es) 2022-03-31
PE20220707A1 (es) 2022-05-04
JP7317210B2 (ja) 2023-07-28

Similar Documents

Publication Publication Date Title
MX2018013662A (es) Sistema de entrega de farmacos para la entrega de agentes antivirales.
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
MD20220043A2 (ro) Compuşi foarte activi împotriva COVID-19
MX2012007410A (es) Compuestos antivirales novedosos.
MD4754C1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
MX2022002897A (es) Profarmacos antivirales y formulaciones de los mismos.
WO2007013047A3 (en) Water-dispersible anti-retroviral pharmaceutical compositions
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
MX2021008536A (es) Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
MX2022001765A (es) Sistema de administracion de medicamentos para la administracion de agentes antiviricos.
CR20220418A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
MX2022013759A (es) Sistema de suministro de farmacos para el suministro de agentes antivirales y contraceptivos.
MX2022006940A (es) Composiciones farmaceuticas.
MX2019015478A (es) Una nanosuspension farmaceutica para el tratamiento de infeccion por vih.
MX2023008004A (es) Derivado de adenosina y composicion farmaceutica que lo comprende.
JOP20220188A1 (ar) عوامل مضادة للفيروسات لعلاج عدوى فيروس نقص المناعة البشرية والوقاية منها
MX2019013819A (es) Oligopeptidos inhibitorios de la angiogenesis y de la funcion vascular.